Avutometinib + Defactinib for Stomach Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications, but you cannot take certain drugs that interact with the study medications, like strong CYP3A4, CYP2C9, P-glycoprotein, or breast cancer resistance protein inhibitors or inducers. If you're on warfarin, you may need to switch to a different blood thinner.
Research Team
Ryan Moy, MD, PhD
Principal Investigator
Columbia University
Eligibility Criteria
This trial is for individuals with diffuse-type stomach cancer. Participants should not have had prior treatment for their condition and must be in a health state that allows them to undergo the study treatments.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Avutometinib 3.2mg orally two times per week for three weeks followed by one week of rest, and Defactinib 200mg twice daily for three weeks followed by one week of rest
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for overall survival and progression-free survival
Treatment Details
Interventions
- Avutometinib
- Defactinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ryan H. Moy, MD, PhD
Lead Sponsor
Verastem Oncology
Collaborator